Navigation Links
BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer
Date:11/21/2008

e Harbor-UCLA Medical Center, Division of Genetics, Department of Pediatrics. Together with his colleague Elizabeth F. Neufeld, Ph.D., of the University of California at Los Angeles (UCLA), Dr. Kakkis discovered how to produce a recombinant form of alpha-L-iduronidase (later to become known as Aldurazyme(R) [laronidase]), the enzyme which people with mucopolysaccharidosis I (MPS I) are lacking. While at BioMarin, Dr. Kakkis was instrumental in guiding Aldurazyme, Naglazyme and Kuvan through development and regulatory approval. He also drove initial phases of development of PEG-PAL pre-clinical, clinical, regulatory and research organizations.

The company is initiating a search for a new Chief Medical Officer. It hopes to have a new Chief Medical Officer by the end of the first quarter of 2009.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase 1 clinical development for the treatment of PKU. For additional information, ple
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related biology technology :

1. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
2. BioMarin to Present at the BioCentury NewsMakers Conference
3. BioMarin to Present at the Rodman & Renshaw 9th Annual Healthcare Conference
4. BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease
5. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
6. BioMarin Appoints Dr. Gordon Vehar, Vice President of Research
7. BioMarin to Present at the Merrill Lynch 2008 Global Healthcare Conference
8. BioMarin Announces Fourth Quarter and Full Year 2007 Financial Results
9. BioMarin to Host First Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, April 29 at 5:00 p.m. ET (23:00 CET)
10. BioMarin to Present at the Morgan Stanley Healthcare Conference
11. BioMarin Announces First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... Toronto, Canada (PRWEB) May 17, 2013 ... to understanding complex biological systems that can help predict ... Keynote speaker Dr. Sergey Stepaniants, Head of Computational Biology ... of computational biology tools to ensure high-quality genomics when ... tools can be applied to complex data sets to ...
(Date:5/17/2013)... 17, 2013 Tooth decay is an epidemic ... signs of the disease. The World Health Organization says that ... of adults have cavities. What are the long-term effects of ... a strong connection between the oral bacterial imbalance and serious ... so rampant, yet it is also 100% preventable? Answer: there ...
(Date:5/16/2013)... New Zealand (PRWEB) May 16, 2013 In ... was invited to speak to doctors in China about ... Australia and NZ, this was her first trip to lecture ... Dr. Hart visited Guangzhou and Fuzhou, home to 12 and ... in China is very high at this point in time. ...
(Date:5/16/2013)...  HealthSparq, a trusted provider of healthcare transparency ... health plans, will debut a new benchmark study ... 2013 conference on June 13.  The presentation will ... insurance companies across the country are thinking about ... for increased healthcare transparency. This ...
Breaking Biology Technology:Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 2HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 3
... May 14 Spherix Incorporated (Nasdaq: SPEX ... a provider of technical and regulatory consulting services to ... it will exhibit at the 2009 BIO International Conference ... New Diabetes and Obesity Control Drug" booth will showcase ...
... Oncothyreon Inc. (NASDAQ: ONTY ) (TSX: ONY) (the ... $0.13 per basic and diluted share for the quarter ended ... million or $0.26 per basic and diluted share for the ... primarily the result of the transfer of manufacturing activities for ...
... 14 The Philadelphia area-based probiotics firm Kibow Biotech ... invited to present at the BIO 2009 Company Forum, ... GA on Tuesday, May 19. BIO is the world,s ... services for more than 1,200 member companies and institutions ...
Cached Biology Technology:Spherix to Exhibit at the BIO 2009 International Convention 2Oncothyreon reports first quarter 2009 financial results 2Oncothyreon reports first quarter 2009 financial results 3Oncothyreon reports first quarter 2009 financial results 4Oncothyreon reports first quarter 2009 financial results 5Kibow Biotech, Inc. to Present at BIO 2009 International Convention: Innovations to Heal, Fuel, and Feed the World 2Kibow Biotech, Inc. to Present at BIO 2009 International Convention: Innovations to Heal, Fuel, and Feed the World 3Kibow Biotech, Inc. to Present at BIO 2009 International Convention: Innovations to Heal, Fuel, and Feed the World 4
(Date:5/17/2013)... finds human-caused climate change may have little impact ... host of recent studies that predict their widespread ... findings, which appear in the journal Global ... of a creature thought to be doomed: ... animals, especially forest lizards, will be hard hit ...
(Date:5/16/2013)... (Maximizing Access to Research Careers) Program has announced ... (ENDO) 95th Annual Meeting in San Francisco, CA ... to promote the entry of students, postdoctorates and ... the basic science community and to encourage the ... Annual Meeting. , Awards are given to poster/platform ...
(Date:5/16/2013)... a gene involved in neurodegenerative disease also plays a ... clock. , In a study of the common ... keeps the clock responsible for sleeping and waking on ... the fruit fly,s sleep-wake cycle is disturbed, making waking ... , The discovery is particularly interesting because mutations ...
Breaking Biology News(10 mins):Climate change may have little impact on tropical lizards 2Gene involved in neurodegeneration keeps clock running 2
... A global collaborative has produced a first draft ... that will lead to insights in agriculture, medicine, conservation ... farm at the University of Illinois will now be ... had their genomes sequenced. Researchers will announce the achievement ...
... / - PDC Biotech GmbH (PDC) today announced the ... Verwaltungs AG (Munich) and Edmond de Rothschild Investment Partners (Paris) co-led ... used to complete preclinical work and the first clinical study of ... for the treatment of preterm labour and primary dysmenorrhea . ...
... 2009) -- A husband and wife team of American paleontologists has ... ago during the early Cretaceous of central Montana. The new ... of the Canadian Journal of Earth Sciences . Ankylosaurs are ... a plate-like armour with two sets of sharp spikes on each ...
Cached Biology News:First draft of the pig: Researchers sequence swine genome 2First draft of the pig: Researchers sequence swine genome 3PDC Biotech GmbH Announces Close of Series A Financing 2PDC Biotech GmbH Announces Close of Series A Financing 3New dinosaur species from Montana 2
Mixing speed from 750-3200RPM, small vortexing orbit of1.0mm...
Request Info...
Autoclavable, variable volumefitted w./ an anti-drip safety valve; borosilicate glass barrelprotected with transparentpolypropylene sleeve; spring-lock cursor design ensuresfine adjustment for exact ...
Spaced cover glasses to promote effective hybridization...
Biology Products: